Our roundup of Canadian small-caps of between $100-million and $2.5-billion in market capitalization making news and on the move today.
The company said it has been awarded the contract under the Canadian Safety and Security Program (CSSP) at Defence Research and Development Canada (DRDC).
Calian said it will support technology services for CSSP and about 21 federal departments and agencies, “providing the ability to scale up Canada’s science and technology capabilities to meet specific operational requirements.”
The contract has a term of up to five years and is valued at approximately $18-million.
It said average daily mutual fund AUM remained flat at $18.9-billion compared to the same period in 2019.
Net mutual fund redemptions of $22-million compared to net redemptions of $103-million a year ago, the company said.
Income was $138.7-million, compared to $107.4-million in the prior year and above expectations of $113.4-million.
Net income of $47.3-million or 60 cents per share compared to $14.4-million or 18 cents a year ago. Adjusted net income was $14.8-million or 19 cents versus $14.6-million or 18 cents a year ago. Analysts were expecting adjusted EPS of 14 cents.
Aurora Cannabis Inc. (ACB-N; ACB-T) reported revenue of $72.1-million for its fourth quarter ended June 30, a 5-per-cent decrease from the prior quarter. The expectation was for revenue of $71.5-million.
Its net loss from continuing operations was $1.86-billion. The company said it recorded “a number of balance sheet adjustments” in the quarter in “to recognize market realities and position the company for future performance.” It recognized a non-cash write-down of goodwill and intangible assets of $1.6-billion, a $135.1-million inventory charge and an $86.5-million writedown on its production facilities.
Recently appointed chief executive officer Miguel Martin said the fourth quarter “demonstrated progress in rationalization of SG&A [selling, general and administrative expenses] and cash burn along with continued leadership in both Canadian and international medical. However, Aurora has slipped from its top position in Canadian consumer, a market that continues to support material growth and opportunity.”
Mr. Martin said his focus is to “re-position the Canadian consumer business immediately.”
In its outlook, the company said net revenue — which will just be from cannabis revenue after divestitures — is expected to be between $60-million and $64-million, compared to $67.5-million of cannabis-only revenue in the fourth quarter.
The company also said it expects to achieve positive adjusted EBITDA in the second quarter of 2021.
Net income of $4-million or 2 cents per share compared to as a net loss of $62.8-million or 47 cents a year ago.
Be smart with your money. Get the latest investing insights delivered right to your inbox three times a week, with the Globe Investor newsletter. Sign up today.